Abstract
We describe a patient with cerebellar ataxia of degenerative nature who was administered high-dose piracetam in a single-blind trial. Piracetam was demonstrated to be highly effective on tandem gait and gait ataxia in daily doses of 60 g. We suggest piracetam has a potential anti-ataxic effect in human cerebellar ataxia when used in considerably higher doses than those indicated for other purposes.
Copyright 2002 Movement Disorder Society
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
Adult
-
Atrophy
-
Cerebellar Ataxia / diagnosis
-
Cerebellar Ataxia / drug therapy*
-
Cerebellar Cortex / pathology*
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Magnetic Resonance Imaging
-
Neurologic Examination / drug effects
-
Neuroprotective Agents / administration & dosage*
-
Neuroprotective Agents / adverse effects
-
Piracetam / administration & dosage*
-
Piracetam / adverse effects
-
Single-Blind Method
-
Spinocerebellar Degenerations / diagnosis
-
Spinocerebellar Degenerations / drug therapy*
-
Treatment Outcome
-
Walking
Substances
-
Neuroprotective Agents
-
Piracetam